Skip to main content

Table 5 A comparison of HTA and MCDA outcomes (economic criteria excluded) for 50 % threshold, multiple HTA restrictions imposed

From: Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs

  HTA
Positive Negative
Unrestricted Time restrictions Limits to specific subpopulation Finanacial restrictions Clinical reasons Economic reasons
MCDA Positive Cystadane, Volibris, Torisel, Glivec (DFSP), Glivec (GIST) Zavesca, Kuvan, Increlex Ventavis, Tracleer, Nexavar (HCC), Nplate, Tasigna, Glivec (MM), Yondelis Zavesca, Tasigna, Yondelis Elaprase, Fabrazyme, Somavert, Torisel Fabrazyme, Somavert, Torisel, Nexavar (RCC)
Negative Vidaza, Glivec (ALL Ph+), Glivec (MDS/MPD), Revatio None Revlimid (MM/S), Sprycel, Atriance) Revlimid (MM/S), Atriance None None